



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/724,571	11/28/2000	John P. Anderson	015270-006444US	6100

21835 7590 11/19/2002

ELAN PHARMACEUTICALS, INC.
INTELLECTUAL PROPERTY DEPARTMENT
800 GATEWAY BOULEVARD
SOUTH SAN FRANCISCO, CA 94080

EXAMINER

WALICKA, MALGORZATA A

ART UNIT	PAPER NUMBER
----------	--------------

1652

DATE MAILED: 11/19/2002

Please find below and/or attached an Office communication concerning this application or proceeding.

Response to Restriction Requirement filed on July 17, 2002 as paper No. 9 and the Supplemental Response to Restriction Requirement/Election of Species Requirement and Amendment filed on September 11, 2002 as Paper 10 are acknowledged. Amendments to the claims have been entered. Claims 78, 81, 84, and 85 are amended. New claims 132-134 are entered.

The reply filed on September 11, 2002 is not fully responsive to the prior Office Action because the following matters are confusing:

Applicants write in "Remarks" that claims 78, 81-85 and 134 are currently under examination. In the next sentence Applicants write that claims 1-77, 79-80 and 86-131 have been withdrawn from consideration. It is therefore unclear whether Applicants include claims 132-133 to the elected claims. Furthermore, Applicants elect β -secretetase substrates of SEQ ID NO: 104, SEQ ID NO: 83, and SEQ ID NO: 97 and state that claim 85 reads on SEQ ID NO: 83; claim 132 and 132⁴ read on SEQ ID NO: 83. The examiner has noted that neither claim 132 nor claim 134 recite SEQ ID NO: 83. SEQ ID NO: 83 is recited by claim 85 only. Claims 132 and 134 recite SEQ ID NO: 97. Please clarify which claims are elected and which claims read on elected substrate sequences.

See 37 CFR 1.111. Since the above-mentioned reply appears to be *bona fide*, applicant is given **ONE (1) MONTH or THIRTY (30) DAYS** from the mailing date of this notice, whichever is longer, within which to supply the omission or correction in order to

Art Unit: 1652

avoid abandonment. EXTENSIONS OF THIS TIME PERIOD MAY BE GRANTED UNDER 37 CFR 1.136(a).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Malgorzata A. Walicka, Ph.D., whose telephone number is (703) 305-7270. The examiner can normally be reached Monday-Friday from 10:00 a.m. to 4:30 p.m.


If attempts to reach examiner by telephone are unsuccessful, the examiner's supervisor, Ponnathapura Achutamurthy, Ph.D. can be reached on (703) 308-3804. The fax number for this Group is (703) 305-3014.

Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionists whose telephone number is (703) 308-0196.

Malgorzata A. Walicka, Ph.D.

Art Unit 1652

Patent Examiner


PONNATHAPUACHUTAMURTHY
SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 1600